Company news
Proteome Sciences Plc (LSE:PRM) news
Proteome Sciences Plc news releases on 6ix. Latest, Sep 16, 2026: Appointment of Non-Executive Director
Press releases & updates
Appointment of Non-Executive Director
September 16, 2026
Further GCLP Chemoproteomics contract secured
September 15, 2026
Target engagement/chemoproteomics contract
June 22, 2026
Annual General Meeting Statement
May 14, 2026
Final results for the year ended 31 December 2025
April 15, 2026
Holding(s) in Company
February 4, 2026
Result of Oversubscribed Retail Offer
January 28, 2026
Retail Offer to raise up to £60,000
January 26, 2026
Two Further Substantial Contracts for PRM
January 6, 2026
Substantial contract for Proteome Sciences
December 8, 2025
Appointment of Nominated Adviser and Broker
November 25, 2025
Interim Results
September 25, 2025
HSBC HOLDINGS PLC ANNOUNCES RESULTS OF ITS TENDER OFFERS FOR FOUR SERIES OF NOTES
September 9, 2025
Result of AGM
May 16, 2025
Final Results
April 10, 2025
Notice of Results and Investor Presentation
April 4, 2025
Contract Win
February 21, 2025
Loan Facility, Trading Update & Directorate Change
December 23, 2024
Interim Results and Directorate Change
September 13, 2024
AGM Statement
May 16, 2024
Completion of new facility in San Diego
January 2, 2024
Trading Update
November 30, 2023
Launch of Single Cell Proteomics Services
October 2, 2023
Investor Presentation
August 30, 2023
Repayment of Loan
June 1, 2023
Expansion into the US
May 12, 2023
Director/PDMR Shareholding
April 14, 2023
Notice of Results
March 29, 2023
Price Monitoring Extension
March 6, 2023
Milestone Payment for TMT®/TMTproT Sales
January 5, 2023
Grant of Options and PDMR/director shareholdings
December 1, 2022
Change of Auditor
October 4, 2022
Second Price Monitoring Extn
September 20, 2022
Appointment of Chief Financial Officer
August 18, 2022
Milestone towards Single Cell Proteomics services
August 3, 2022
Change of Registered Office
May 26, 2022
Substantial Contract Win
May 12, 2022
Director shareholding
April 1, 2022
Loan amendment
March 30, 2022
PRM,INmune Bio presenting biomarker discovery data
November 5, 2021
Issuance of key TMT Patent
May 19, 2021
Loan Amendment
March 30, 2021
Trading Update and Notice of Results
March 26, 2021
Year End Trading Update
January 25, 2021
Appointment of Chief Executive Officer
September 14, 2020
Notice of Annual General Meeting
June 2, 2020
Response to Share Price Movement
April 28, 2020
Posting of Results, AGM update and loan amendment
April 20, 2020
Further Year End Trading Update, Milestone Payment
February 11, 2020
Trading Update and Announcement of Board Changes
October 31, 2019